Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 675       

   Table of Contents      
CLINICAL IMAGES
Year : 2017  |  Volume : 146  |  Issue : 1  |  Page : 141

Complete response of metastatic gastric cancer to chemoimmunotherapy


Department of Medical Oncology, Nagoya Memorial Hospital, Nagoya, Japan

Date of Submission08-Feb-2016
Date of Web Publication22-Nov-2017

Correspondence Address:
Kenji Ina
Department of Medical Oncology, Nagoya Memorial Hospital, Nagoya
Japan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijmr.IJMR_132_16

Rights and Permissions

How to cite this article:
Ina K, Furuta R. Complete response of metastatic gastric cancer to chemoimmunotherapy. Indian J Med Res 2017;146:141

How to cite this URL:
Ina K, Furuta R. Complete response of metastatic gastric cancer to chemoimmunotherapy. Indian J Med Res [serial online] 2017 [cited 2019 Dec 12];146:141. Available from: http://www.ijmr.org.in/text.asp?2017/146/1/141/219008



A 64 yr old man with a complaint of abdominal pain, presented to the department of Medical Oncology, Nagoya Memorial Hospital, Nagoya, Japan, in August 2010. Computed tomography demonstrated multiple liver tumours [Figure 1]. Advanced gastric cancer type 2 was diagnosed using gastrointestinal videoendoscopy [Figure 2]. Triple therapy with S-1, paclitaxel and cisplatin in combination with lentinan, a representative mushroom β-glucan, was initiated. Re-evaluation after six cycles showed complete disappearance of the primary gastric lesion in April 2011 and only S-1 was continued in combination with lentinan. Complete disappearance of liver metastases and primary gastric lesions was observed in April 2013 [Figure 3] and [Figure 4]. Chemoimmunotherapy was stopped due to grade 3 skin-related adverse effects. During the follow up period of 33 months no evidence of recurrence was seen.
Figure 1: Computed tomography scan showing multiple liver tumours in both lobes before the initiation of chemoimmunotherapy (arrow heads).

Click here to view
Figure 2: Gastrointestinal videoendoscopy showing round wall with central ulceration in the antrum of the stomach (arrow heads) on admission. The histological diagnosis of biopsied samples was well-differentiated adenocarcinoma.

Click here to view
Figure 3: Computed tomography scan demonstrating complete disappearance of metastatic liver tumours after chemoimmunotherapy.

Click here to view
Figure 4: Gastrointestinal videoendoscopy showing complete resolution of the primary gastric lesions after chemoimmunotherapy.

Click here to view





    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4]


This article has been cited by
1 Antineoplastics
Reactions Weekly. 2018; 1684(1): 32
[Pubmed] | [DOI]
2 Lentinan as an immunotherapeutic for treating lung cancer: a review of 12years clinical studies in China
Yiran Zhang,Meng Zhang,Yifei Jiang,Xiulian Li,Yanli He,Pengjiao Zeng,Zhihua Guo,Yajing Chang,Heng Luo,Yong Liu,Cui Hao,Hua Wang,Guoqing Zhang,Lijuan Zhang
Journal of Cancer Research and Clinical Oncology. 2018;
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Article Figures

 Article Access Statistics
    Viewed485    
    Printed1    
    Emailed0    
    PDF Downloaded139    
    Comments [Add]    
    Cited by others 2    

Recommend this journal